China Pharma (CPHI) Competitors $1.90 +0.04 (+2.09%) Closing price 07/25/2025 03:56 PM EasternExtended Trading$1.90 -0.01 (-0.47%) As of 07/25/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock CPHI vs. DARE, AYTU, LSTA, PULM, GDTC, ELEV, NAII, CVKD, CMMB, and RLMDShould you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include Dare Bioscience (DARE), Aytu BioPharma (AYTU), Lisata Therapeutics (LSTA), Pulmatrix (PULM), CytoMed Therapeutics (GDTC), Elevation Oncology (ELEV), Natural Alternatives International (NAII), Cadrenal Therapeutics (CVKD), Chemomab Therapeutics (CMMB), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry. China Pharma vs. Its Competitors Dare Bioscience Aytu BioPharma Lisata Therapeutics Pulmatrix CytoMed Therapeutics Elevation Oncology Natural Alternatives International Cadrenal Therapeutics Chemomab Therapeutics Relmada Therapeutics China Pharma (NYSE:CPHI) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Do insiders & institutionals believe in CPHI or DARE? 6.7% of Dare Bioscience shares are held by institutional investors. 17.3% of China Pharma shares are held by insiders. Comparatively, 4.0% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer CPHI or DARE? In the previous week, Dare Bioscience had 2 more articles in the media than China Pharma. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for China Pharma. China Pharma's average media sentiment score of 1.25 beat Dare Bioscience's score of 0.63 indicating that China Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CPHI or DARE more profitable? Dare Bioscience has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Dare Bioscience's return on equity of 0.00% beat China Pharma's return on equity.Company Net Margins Return on Equity Return on Assets China Pharma-85.56% -63.93% -31.42% Dare Bioscience N/A N/A -8.14% Which has higher earnings & valuation, CPHI or DARE? China Pharma has higher revenue and earnings than Dare Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina Pharma$4.30M1.45-$3.08MN/AN/ADare Bioscience$10K2,274.45-$4.05M-$0.17-15.12 Which has more volatility & risk, CPHI or DARE? China Pharma has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Do analysts prefer CPHI or DARE? Dare Bioscience has a consensus price target of $12.00, indicating a potential upside of 366.93%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than China Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dare Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryDare Bioscience beats China Pharma on 10 of the 14 factors compared between the two stocks. Get China Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPHI vs. The Competition Export to ExcelMetricChina PharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$6.17M$786.26M$5.70B$21.04BDividend YieldN/A4.84%4.58%3.59%P/E RatioN/A1.4428.4128.45Price / Sales1.4525.35432.3171.70Price / CashN/A19.5636.2222.92Price / Book2.726.918.674.68Net Income-$3.08M-$4.17M$3.25B$995.51M7 Day Performance7.94%1.01%4.25%1.65%1 Month Performance9.68%3.65%10.51%4.54%1 Year Performance-92.38%9.83%35.68%10.00% China Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPHIChina Pharma0.4773 of 5 stars$1.90+2.1%N/A-92.4%$6.17M$4.30M0.00250Positive NewsGap DownDAREDare Bioscience1.7891 of 5 stars$2.61-2.6%$12.00+359.8%-28.6%$23.10M$25.91K-15.3530Gap UpAYTUAytu BioPharma4.1357 of 5 stars$2.56+8.0%$10.00+290.6%-2.6%$22.98M$81.66M-3.56160LSTALisata Therapeutics2.944 of 5 stars$2.64+2.3%$23.50+790.2%-21.3%$22.76M$1M-1.1530Gap DownPULMPulmatrix0.8547 of 5 stars$6.08+0.2%N/A+166.4%$22.19M$1.92M-1.8220GDTCCytoMed Therapeutics1.4606 of 5 stars$2.02+1.0%$5.00+147.5%-5.3%$22.10M$69.50K0.00N/AUpcoming EarningsELEVElevation Oncology2.8522 of 5 stars$0.37-2.1%$3.39+827.6%N/A$21.62MN/A-0.4540High Trading VolumeNAIINatural Alternatives International1.1094 of 5 stars$3.47+3.3%N/A-35.7%$21.45M$113.80M-2.50290CVKDCadrenal Therapeutics3.092 of 5 stars$10.81+0.2%$32.00+196.0%N/A$21.30MN/A-1.174Positive NewsCMMBChemomab Therapeutics3.0925 of 5 stars$1.12+1.8%$8.50+658.9%-8.4%$21.12MN/A-1.4720Gap UpRLMDRelmada Therapeutics4.8099 of 5 stars$0.63+1.9%$5.00+699.4%-84.0%$20.76MN/A-0.2510Positive NewsGap Down Related Companies and Tools Related Companies Dare Bioscience Competitors Aytu BioPharma Competitors Lisata Therapeutics Competitors Pulmatrix Competitors CytoMed Therapeutics Competitors Elevation Oncology Competitors Natural Alternatives International Competitors Cadrenal Therapeutics Competitors Chemomab Therapeutics Competitors Relmada Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPHI) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
